Abstracts tagged "Inflammation"

Abstract Number: 0790 • ACR Convergence 2023
Transcriptomic Analyses of Lung Tissues Reveals Potential Key Genes Associated with Progression of Systemic Sclerosis-Interstitial Lung Disease (SSc-ILD)
Yehya Al-Adwi¹, Johanna Westra¹, Harry van Goor¹, Leon.C.L.T van Kempen², Wim Timens¹, C.Tji Gan¹ and Douwe J Mulder¹, ¹University Medical Center Groningen, Groningen, Netherlands, ²UMCG and University of Antwerp, Groningen, Netherlands
Background/Purpose: SSc-ILD is the leading cause of death in SSc affecting around 50% of the patients. Lung tissue of patients with early-stage SSc-ILD is characterized…
Abstract Number: 0975 • ACR Convergence 2023
Association of HLA-DRB1 Alleles with Ischemic Events and Mortality in a Multi-ethnic Community-living Population
Manmeet Kaur¹, Ronit Katz², Michael H. Criqui¹, Maripat Corr¹, Wendy S. Post³, Matthew Budoff⁴, Gerald P. Morris⁵ and Jan Hughes-Austin⁵, ¹University of California San Diego, San Diego, CA, ²University of Washington, Seattle, WA, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of California Los Angeles, Los Angeles, CA, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Human leukocyte antigen (HLA) DRB1 alleles with specific common amino acids referred to as "the shared epitope (SE)", have been linked to cardiovascular mortality…
Abstract Number: 1280 • ACR Convergence 2023
Systemic Inflammation Is Associated with Incident Valvular Heart Disease in Patients with Rheumatoid Arthritis: A Multicenter, Prospective Cohort Study
Tate Johnson¹, Yangyuna Yang¹, Punyasha Roul¹, Joshua Baker², Brian Sauer³, Grant Cannon⁴, Gary Kunkel⁵, Bryce Binstadt⁶, Amy Joseph⁷, K Wysham⁸, Aleksander Lenert⁹, Gail Kerr¹⁰, Andreas Reimold¹¹, Michael Duryee¹, Geoffrey Thiele¹, Ted R Mikuls¹² and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶University of Minnesota, Minneapolis, MN, ⁷Washington University / St. Louis VA, St. Louis, MO, ⁸VA Puget Sound/University of Washington, Seattle, WA, ⁹University of Iowa, Iowa City, IA, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹University of Texas Southwestern Medical Center, Dallas, TX, ¹²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The risk of aortic stenosis is increased in people with RA and valvular heart disease (VHD) is among the most over-represented causes of cardiovascular…
Abstract Number: 1732 • ACR Convergence 2023
Immunopathogenesis and Preclinical Trials in a Humanized Mouse Model of Rheumatoid Arthritis(RA)
Huiyi Wang¹, Kangkang Luo¹, Shuxin Xu¹, Jiayin Zhou¹, Santi Chen², Jun wang², Wenzhao Li², Jing Zhao¹ and Cunxiang Ju¹, ¹GemPharmatech CO., Ltd., Nanjing, China, ²GemPharmatech LLC, La Jolla, CA
Background/Purpose: The differences between human and mouse immune systems make it challenging to accurately reflect the immunopathogenesis of autoimmune diseases in patients. Therefore, translational research…
Abstract Number: 1784 • ACR Convergence 2023
Dendritic Cell-specific TNFR2 Depletion Reduces Psoriatic Arthritis-like Disease in a Mouse Model
Raminderjit Kaur¹, M. Elaine Husni², Unnikrishnan Chandrasekharan³ and Roberta Brambilla⁴, ¹Cleveland Clinic, Cleveland,, OH, ²Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ³Cleveland Clinic, Cleveland, OH, ⁴University of Miami Miller School of Medicine, Miami,, FL
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, progressive autoimmune condition that affects both the skin and joints. It is characterized by increased levels of the…
Abstract Number: 2352 • ACR Convergence 2023
High Serum C-X-C Motif Chemokine Ligand 10 (CXCL10) Potentially Predicts New Onset of Systemic Sclerosis-Interstitial Lung Disease
Yehya Al-Adwi, Isabella Atzeni, Berber Doornbos-van der Meer, Marcel J van der Leij, Bart-Jan Kroesen, Alja Stel, Wim Timens, C.Tji Gan, Harry van Goor, Johanna Westra and Douwe J Mulder, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Systemic sclerosis-interstitial lung disease (SSc-ILD) is the leading cause of death in SSc patients. There is an unmet need for predictive biomarkers of ILD…
Abstract Number: PP10 • ACR Convergence 2023
Saved by Plants: How a Necessary Lifestyle Change Led to a Happier Life with Decreased Rheumatoid Arthritis Pain and Fatigue
Shelley Fritz, Global Healthy Living Foundation, Nyack, NY
Background/Purpose: After my RA diagnosis over eleven years ago, I was optimistic that the first biologic DMARD I took would slow the progression of my…
Abstract Number: 0042 • ACR Convergence 2023
Effect of the Inflammatory Microenvironment Induced by Monocytes on Fibroblasts and Modulatory Action of Human Dental Pulp Stem Cells
Monia Maccaferri¹, Alessandra Pisciotta¹, Gianluca Carnevale¹, Carlo Salvarani² and ELISA PIGNATTI¹, ¹University of Modena and Reggio Emilia, Modena, Italy, ²Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: The pathophysiology of viral infection is related to elevated levels of inflammatory cytokines therefore also of the excessive activation of monocytes. Prolonged inflammation can…
Abstract Number: 0373 • ACR Convergence 2023
Potential Tear-Based Uveitis Biomarkers in Children with JIA: A Pilot Study
Ilaria Maccora¹, Mekibib Altaye², Tiffany Nguyen³, Kenneth Greis⁴, Wendy Haffey⁴, Theresa Hennard⁵, Alyssa Sproles², Sherry Thornton², Virginia Miraldi Utz⁵ and Sheila Angeles-Han², ¹PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Eye Institute, Cincinnati, OH, ⁴University of Cincinnati, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Children with oligoarticular JIA are at increased risk of developing uveitis. JIA category, ANA positivity, ≤4 years JIA duration, and < 6 years old…
Abstract Number: 0813 • ACR Convergence 2023
Sonographic Crystal Deposits and Power-Doppler Signal in Patients with Gout Fulfilling Remission Criteria: A Multicenter Study Enrolling 115 Participants
Mariano Andrés¹, Nalia Domínguez-Lirón², Enrique Calvo-Aranda³, Esther Vicente Rabaneda⁴, Agustín Martínez-Sanchís¹, Francisca Sivera⁵, Diana Peiteado⁶, Alejandro Prada⁷, Blanca Garcia⁸, Basilio Rodríguez⁹, BORIS ANTHONY BLANCO CACERES¹⁰, José Antonio Bernal¹¹, Santos Castañeda¹², Laura Barrio⁷, Sonia Minguez⁹, Mónica Vázquez Díaz¹³, José Miguel Senabre¹¹, Cristina Bohorquez¹⁴, Silvia Gómez-Sabater¹⁵, Rocío Caño-Alameda¹⁵ and Eugenio De Miguel¹⁶, ¹Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ²Miguel Hernández University, Alicante, Spain, ³Hospital Universitario Infanta Leonor, Madrid, Spain, ⁴Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁵Elda General University Hospital, Elda, Spain, ⁶Hospital La Paz, Madrid, Spain, ⁷Hospital Universitario de Torrejón, Madrid, Spain, ⁸Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ⁹Fundació Althaia, Manresa, Spain, ¹⁰Hospital Universitario Ramon y Cajal, Madrid, Spain, ¹¹Hospital Marina Baixa, Villajoyosa, Spain, ¹²Hospital Universitario de la Princesa, Madrid, Spain, ¹³Hospital Ramon y Cajal, Madrid, Spain, ¹⁴Rheumatology Unit, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ¹⁵Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, ¹⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: The prevalence of sonographic monosodium urate (MSU) crystal deposition and inflammation in patients with gout in remission is unknown. In 2022, we reported a…
Abstract Number: 1041 • ACR Convergence 2023
Efficacy of Apremilast on Peripheral and Axial Inflammation in Patients with Psoriatic Arthritis Based on Whole-Body Magnetic Resonance Imaging
Mikkel Østergaard¹, Mikael Boesen², Walter P. Maksymowych³, Robert Lambert⁴, Guillermo Valenzuela⁵, Michael Bubb⁶, Olga Kubassova⁷, Jyotsna Reddy⁸, Stephen Colgan⁹, Yuri Klyachkin¹⁰, Cynthia Deignan¹¹, Zhenwei Zhou⁸ and Philip J. Mease¹², ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ²Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Naerum, Denmark, ³Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁴Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ⁵Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁶University of Florida, Gainesville, FL, ⁷Image Analysis Group, Philadelphia, PA, ⁸Amgen, Inc., Thousand Oaks, CA, ⁹Amgen, Inc., Halton Hills, ON, Canada, ¹⁰Amgen, Inc., Lexington, KY, ¹¹Amgen, Inc., Agoura Hills, CA, ¹²Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Apremilast is an oral phosphodiesterase 4 inhibitor with a unique immunomodulatory mechanism of action and is approved for the treatment of psoriatic arthritis (PsA).…
Abstract Number: 1322 • ACR Convergence 2023
Efzofitimod, a First-in Class NRP2-targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models
Christoph Burkart, Clara Polizzi, Lisa Eide, Max Pastenes, David Siefker and Leslie Nangle, aTyr Pharma, San Diego, CA
Background/Purpose: Efzofitimod, a novel immunomodulator, has shown clinical proof-of-concept in a Phase 1b/2a clinical trial in patients with pulmonary sarcoidosis and is currently enrolling a…
Abstract Number: 1735 • ACR Convergence 2023
An Unorthodox HLA-DRhiCD15+ ‘Hybrid’ Population in Rheumatoid Arthritis Characterized Using Spectral Cytometry
Christian Geier¹, Haani Qudsi², Jihad BenGabr¹, Robert Winchester³ and Andras Perl⁴, ¹SUNY Upstate Medical University, Syracuse, NY, ²Norton College of Medicine, SUNY Upstate Medical University, Syracuse, NY, ³Columbia University, New York, NY, ⁴SUNY, Syracuse, NY
Background/Purpose: A variant of HLA-DR confers the strongest genetic risk for rheumatoid arthritis (RA) suggesting that DRhi cells are important in RA. We previously found…
Abstract Number: 1793 • ACR Convergence 2023
Goblet Cell Specific Anti-Apoptotic Role of Interleukin-24 in Spondyloarthritis-Associated Ileitis
Amy Cameron¹, Rabina Giri², Jakob Begun², Timothy Wells¹, Ranjeny Thomas³ and Anne-Sophie Bergot¹, ¹Frazer Institute, The University of Queensland, Woolloongabba, Australia, ²Mater Research Institute-UQ, Woolloongabba, Australia, ³Frazer Institute, The University of Queensland, Brisbane, Australia
Background/Purpose: The loss of intestinal barrier integrity is a key contributor to gut inflammation, however the mechanism behind this dysregulation is not well understood. The…
Abstract Number: 2358 • ACR Convergence 2023
Neutrophil Extracellular Traps Induce Endothelial-to-Mesenchymal Transition and Associate with Vascular Complications in Scleroderma
Ramadan Ali¹, Wenying Liang¹, Claire Shiple¹, Rosemary Gedert², Suiyuan Huang¹, Cyrus Sarosh¹, Eliza Pei-Suen Tsou¹, Dinesh Khanna¹ and Jason Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Onsted, MI
Background/Purpose: Systemic sclerosis (SSc, also known as scleroderma) is a disease characterized by fibrosis, autoimmunity, and vasculopathy. Many devastating complications such as digital ulcerations, scleroderma…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].